Sipavibart clinical trials

A Phase I/III Randomized, Double-blind Study to Evaluate the Safety, Efficacy, and Neutralizing Activity of AZD5156/AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants with Conditions Causing Immune Impairment

This study is testing a new medicine, Sipavibart (also called AZD5156/AZD3152), to see if it can prevent COVID-19 in people with weaker immune systems. It compares the new medicine to an existing one called Evusheld or a dummy treatment, focusing on how safe and effective it is.